SMC is a consortium of stakeholders from Area Drug and Therapeutic Committees (ADTCs) and representation is derived from ADTCs across NHSScotland.
New members are sourced from ADTCs, and from the nominations received the SMC Executive identifies replacements for those leaving the Committee. The term of membership on SMC is for an initial period of three years, but may be extended. Members of the New Drugs Committee, which is a sub-committee of SMC, are also selected from nominations received from ADTCs.
SMC also has three pharmaceutical industry representatives who provide a broad industry perspective. Recruitment of these members is facilitated through ABPI and ratified by the SMC Executive.
The SMC has three public partner representatives who ensure the views of patients, carers and members of the public are taken into account. Recruitment of these volunteer public partners takes place through Healthcare Improvement Scotland's Public Involvement team and is ratified by the SMC Executive.